Background and aims: Colorectal cancer (CRC) harbours different types of DNA alterations, including microsatellite instability (MSI). Cancers with high levels of MSI (MSI-H) are considered to have a good prognosis, probably related to lymphocyte infiltration within tumours. The aim of the present study was to characterise the intratumoural expression of markers associated with the antitumour immune response in mismatch repair (MMR)-proficient (MSS) colon cancers.
Methods: Ninety human colon cancers (T) and autologous normal colon mucosa (NT) were quantified for the expression of 15 markers of the immune response with quantitiative reverse transcription-PCR (qRT-PCR). mRNA expression levels were correlated with MMR status. Immunohistochemistry (IHC) was performed using both interleukin 17 (IL17) and CD3 antibodies.
Results: Expression of cytotoxic markers (FasL, granzyme B and perforin), inflammatory cytokines (IL1β, IL6, IL8, IL17 and transforming growth factor β (TGFβ)) and a marker of regulatory T cells (forkhead box P3 (Foxp3)) was significantly higher in tumours than in autologous normal tissues. Adjusting for MMR status, higher tumoural expression of both granzyme B and perforin was associated with the MSI-H phenotype, and the perforin T/NT ratio was higher in MSI-H tissues than in MSS tissues. Higher tumoural expression of Foxp3, IL17, IL1β, IL6 and TGFβ was associated with the MSS phenotype, and the IL17 T/NT ratio was higher in MSS tissues than in MSI-H tissues as assessed by both qRT-PCR and IHC.
Conclusions: Immune gene expression profiling in CRC displayed different patterns according to MMR status. Higher Foxp3, IL6, TGFβ and IL17 expression is a particular determinant in MMR-proficient CRC. These may be potential biomarkers for a new prognostic “test set” in sporadic CRCs.
Statistics from Altmetric.com
Colorectal cancer (CRC) is the second leading cause of cancer mortality in the Western world, despite recent advances in surgery, radiotherapy and chemotherapy.1 Tumour progression of CRCs is governed by either genetic or epigenetic changes intrinsic to cancer cells, and by environmental factors. Approximately 15–20% of sporadic CRCs and nearly all large bowel malignancies in the hereditary non-polyposis colorectal cancer (HNPCC) syndrome are characterised by widespread microsatellite instability.2–4 Microsatellite instability is a genome-wide instability in repetitive DNA sequences observed at the nucleotide level, and it is caused by the inactivation or loss of expression of the mismatch repair (MMR) genes: hMSH2, hMLH1, hPMS1, hPMS2, hMSH6/GTBP or MSH3, as a result of either mutations or epigenetic silencing.5 Besides MMR-deficient (MSI-H) cancer, the majority of sporadic CRSs are MMR proficient (MSS) tumours, with chromosomal instability in some cases.6 7
Most studies revealed longer disease-free and overall survival for patients with MSI-H CRC than for patients with MSS CRC,8–12 even in the case of deep local invasion of the primary tumour.13 These studies suggested a protective role for T lymphocytes, which clearly infiltrated more extensively in MSI-H than in MSS CRCs.14 Pronounced lymphocytic infiltration of tumours has long been associated with an improved prognosis.15 16 MSI in combination with a high content of intraepithelial cytotoxic lymphocytes was related to improved overall survival in a group of exclusively right-sided CRCs,17 18 suggesting that a combination of both the tumour’s local lymphocytosis and MMR characterization may be useful for a more accurate prognostic assessment. Contradictory results come from mouse models of CRC, and these results are consistent with the association between either chronic inflammation19 20 or an increased number of inflammatory cells in tumours21 and tumour progression.
To determine the putative impact of microsatellite status on the antitumoural immune response, we analysed histological and molecular features of tumours in patients with sporadic CRCs. We also developed a quantitative PCR assay for 15 inflammatory and T lymphocyte markers in tumours with reference to the MMR status.
PATIENTS AND METHODS
This retrospective analysis included a group of 45 patients from a consecutive cohort survey study in Henri Mondor Hospital. To be eligible, patients had to have undergone surgery of primary rectal or colon tumours, for which both frozen and paraffin-embedded tumoural and normal tissues were available in the tissue collection bank. None had known hereditary cancer, ulcerative colitis or Crohn’s disease. Consecutive patients were routinely informed about biological research on tissues that did not include hereditary genetic characterisation. Their tissue materials could be used for the current study except if “formal opposition” was mentioned to doctors. The ethical committee approved the procedure.
Histology and pathology
Tissues were immediately examined after surgery, and normal and tumoural representative samples were frozen, fixed in formalin, and archived in a tissue collection bank. Diagnoses and tumour descriptions were done on H&E-stained tissues according to the pTNM classification. Histopathology was further examined for lymphocyte infiltration and for a mucous component.
Analysis of MMR status by immunohistochemistry
Representative samples from adenocarcinoma and normal mucosa adjacent to the tumour were selected in each case and paraffin sections were sent to an automated immunostainer. Tissue sections were incubated in citrate buffer with the following antibodies: G168-728 antibody (recognises hMLH1 antigen; the antibody was diluted 1:40; Pharmingen, San Diego California, USA), FE11 antibody (recognises hMSH2 antigen; the antibody was diluted 1:25; Calbiochem, Cambridge, Massachusetts, USA), 44 antibody (recognises hMSH6; the antibody was diluted 1:100; Zymed Laboratories Inc., South San Francisco, California, USA), all in a boiling water bath. An avidin–biotin complex (ABC Vectastain Kit, Vector Laboratories, Burligame, California, USA) was used to reveal the antigen. Positive controls included slides from tumours with normal expression of hMLH1, hMSH2 and hMSH6; negative controls included slides with no primary antibodies. Two observers with no prior knowledge of the PCR results assessed all cases independently, and cases with discrepancies were further evaluated until agreement was reached between the observers.
Analysis of IL17 expression by immunohistochemistry
Representative samples (n>5) from tumoural and autologous normal mucosa were selected for each case, and paraffin-embedded sections (4 µm) were treated by boiling in citrate buffer (pH 6) in a microwave (800 W, 5 min ×3). Endogenous peroxidase activity was blocked by incubation in 3% hydrogen peroxide for 20 min followed by a wash in phosphate-buffered saline (PBS) for 5 min. Non-specific antibody-binding sites were coated by the addition of a horse serum (1:20 in PBS, for 25 min). Serum was then removed and antihuman IL17 goat antibody (R&D Systems, Lille, France) diluted in the PBS (1:40) was added to the tissue sections (room temperature for 1 h). Immunohistochemical staining was undertaken using a Vectastain Universal Elite kit according to the manufacturer’s instructions (Vector Laboratories). The chromagen, Sigmafast DAB (3′,3′-diaminobenzidine) (Sigma-Aldrich, St Louis, Missouri, USA), was incubated with the tissue sections in the dark (room temperature for 4 min). The sections were then counterstained with haematoxylin.
For double staining IL17/CD3, the goat antihuman IL17 antibody (diluted 1:40) was applied first and incubated for 2 h. Immunohistochemical staining was undertaken using a Vectastain AP kit according to the manufacturer’s instructions (Vector Laboratories) and visualization was done with Naphthol/Fast Red (Sigma-Aldrich). Subsequently, a rabbit antihuman CD3 (diluted 1:50 in PBS; Dako, France) was incubated for 1 h. Immunohistochemical staining was undertaken using the ImmPRESS system (Vector Laboratories) and visualization was done with DAB substrate.
Analysis of microsatellite stability by PCR
Formalin-fixed paraffin-embedded (FFPE) sections from tumours were stained with H&E, and were macrodissected if necessary to select a tissue fragment comprising >40% tumour cells. Normal and tumour autologous DNA was extracted from a 50 µm FFPE or frozen tissue section with QiAmp DNA mini kits (Qiagen, Courtaboeuf, France), according to the manufacturer’s instructions. The genetic instability (MSI-H) status of the tumours was established using pentaplex PCR for markers as described by Suraweera et al.22 Microsatellites were co-amplified in a single 20 µl pentaplex fluorescent PCR, containing 0.1 µM Bat-25, 0.25 µM Bat-26 and NR-22, 0.5 µM NR-24 and NR-21 primers, 0.15 mM dNTP, 1.5 mM MgCl2, 1× GeneAmp PCR Buffer II (Applied Biosystems, Courtaboeuf, France), 50 ng of genomic DNA and 0.5 U of AmpliTaq Gold DNA polymerase (Applied Biosystems). The PCR program was denaturation (95°C, 10 min), then 35 amplification cycles (denaturation (95°C, 30 s), annealing (55°C, 45 s) and extension (72°C, 30 s)), and a final elongation step (72°C, 7 min). Separation and detection of the fluorescent PCR products were performed on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems), and the data were analysed with GeneScan Analysis Software (Applied Biosystems). The MSI-H phenotype was defined as the detection of length alterations of at least three markers in tumoural versus normal DNAs from the same individual.22 We found that 31/45 tumoural tissues had the MSS phenotype, and 14/45 had the MSI-H phenotype.
Quantitative reverse transcription-PCR
Total RNA was prepared from 90 colorectal tumoural or autologous non-tumoural specimens, using Trizol® reagent (Gibco-BRL, Life Technologies, Cergy-Pontoise, France) following the manufacturer’s protocol. To avoid misinterpretation of the variability in marker gene expression due to heterogeneity of the cellular distribution and/or leucocyte densities in tissue samples, 10 sections of 50 µm for each sample were verified before extracting total RNA. Microdissection was used if necessary to select tumour sections with tumoural cells >60% of total. We normalised the ratio of mRNA copy number of the gene of interest/CD3 mRNA for each sample. First-strand cDNA was synthesized in reverse transcription samples, each containing: 2 µg of total RNA isolated from colorectal tissue, 16 U/μl M-MLV reverse transcriptase (Gibco-BRL), 4 μM oligo(dT)12–18 (Amersham-Pharmacia Biotech, Saclay, France) and 0.8 mM mixed dNTPs (Amersham-Pharmacia Biotech). Quantitative reverse transcription-PCR (RT-PCR) was performed in a LightCycler 2.0 System (Roche Diagnostics, Meylan, France) using a SYBR Green PCR kit or a Hybridization Probes PCR Kit from Roche Diagnostics, as previously described.23 24 The sequences of primers and probes are indicated in the Supplementary data. Normalisation was achieved by quantification of the expression of the control housekeeping gene (HKG) β2µglobulin, which was chosen as the control among three HKGs tested because of its stable expression in tumoural and non-tumoural specimens (data not shown). All PCR conditions were adjusted in order to obtain equivalent optimal amplification efficiency between the different assays. Chemokine receptor 1 (CXCR1), CD3, IL8, IL17, granzyme A (GzA), perforin, and FoxP3 mRNA expression was quantified by the relative quantification of real-time PCR according to Gibson et al,25 using the SYBR Green PCR Kit, and using peripheral blood mononuclear cells stimulated with phorbol myristate acetate and ionomycin for 1 h as the calibrator sample. CD3, IL1β, tumour necrosis factor α (TNFα), IL6, interferon γ (IFNγ), IL4, TGFβ, IL10, GzB and FasL mRNA expression was quantified by absolute quantification of real-time PCR using the Hybridization Probes PCR Kit from Roche Diagnostics. The copy number for all target genes and for the HKG was obtained by plotting sample Ct values against the standard curve obtained by analysing the corresponding “quantitative DNA standard”26 dilution series using the LightCycler software 4.0, and the magnitude of target gene mRNA expression is calculated as the copy number of the target gene per 106 copies of β2µglobulin. All PCR experiments were done in duplicate.
Results of the quantification of CD3, IL8, CXCR1, IL1β, IL6, TGFβ and TNFα expression are presented as the median and interquartile range (IQR) of the ratio of the immune marker gene to HKG mRNA expression. IL4, IL10, IL17, Foxp3, FasL, perforin, GzA and GzB are mainly expressed in CD3 mRNA-expressing leucocytes. Therefore, for normalisation between specimens, we used the ratio of mRNA copy number of each marker gene/CD3.
Non-parametric tests were used because of the non-normal distributions of mRNA levels. Overall differences in immune marker expression between the tumoural (T) and autologous non-tumoural (NT) specimens were analysed by using the paired non-parametric Wilcoxon signed-rank test. For significant variations, gene expression levels between tumoural and non-tumoural specimens were also compared in each phenotypic subgroup (MSI-H and MSS). Differences between MSI-H and MSS phenotypes were evaluated by comparing the T/NT ratio of mRNA expression using the two-sample Wilcoxon rank-sum test. All tests were two-tailed. An adjustment for multiple testing was done using the Bonferroni correction, and p values ⩽0.003 (0.05/15 = 0.0033) were considered statistically significant. Data were analysed using Stata Statistical software (StataCorp 2003, Release 8.0, College Station, Texas, USA)
Characterisation of patients with CRCs
Patients with the MSI-H phenotype were not significantly different from those with the MSS phenotype in terms of age, diagnosis, therapy or surveillance procedures (table 1). The rate of tumour relapse within a 36-month follow-up was not different depending on MMR status. Tumours with the MSI-H phenotype were right-sided with significantly different histopathological features: they had more lymphocyte infiltration and a greater mucoid component, and less local or systemic tumour cell extension.
The MSI-H phenotype correlates with the presence of cytotoxic markers
The CD3 mRNA copy number in tumoural (T) tissues was not significantly different from that in autologous (NT) tissue fragments (0.18 (0.13 to 0.28) vs 0. 17 (0.11 to 0.26)) when all samples were considered (irrespective of MMR status). The CD3 T/NT ratio did not differ between MSI-H and MSS tissues. The expression ratios of the cytotoxic parameters, FasL/CD3, perforin/CD3 and GzB/CD3, were significantly higher in tumour tissues than in autologous NT specimens (table 2). Adjusting on MMR status, only the perforin T/NT ratio was higher in MSI-H tissues than in MSS tissues. The expression of GzB/CD3 was significantly higher in tumour (as compared with NT) specimens only if they had an MSS phenotype. The GzA/CD3 ratio did not differ between tumoural and autologous NT specimens.
MSS phenotype and higher Foxp3 and IL17 expression in tumour infiltrates
Overall analysis showed that the expression ratios IL17/CD3 and Foxp3/CD3 (table 2), and IL8, IL1β, IL6 and TGFβ expression (table 3) were significantly higher in tumour tissues than in autologous NT specimens. However, adjusting for MMR status, the higher expression of Foxp3, IL17, IL1β, IL6 and TGFβ was observed only in MSS phenotype tumours (tables 2 and 3). The IL17 T/NT ratio was higher in MSS tissues than in MSI-H tissues. Moreover, quantification by qRT-PCR of IL22 expression, another IL17-producing T cell- (TH-17 cell) secreted cytokine, showed IL22 overexpression in MSS tumour tissues compared with MSI-H tumour tissues (p = 0.042 for the ratio difference between MSI T/NT and MSS T/NT). The IL10/CD3, IL4/CD3 ratios (table 2), and CXCR-1 and TNF expression (table 3) did not differ between the tumoural and autologous non-tumoural specimens. Expression of IFNγ was not detected in any specimen.
IL17-immunoreactive cells were rarely detected in normal tissues in the lamina propria (fig 1A). However, their number was higher in tumour sections than in autologous normal tissues. IL17 cell infiltration was higher in MSS tumours than in MSI tumours (fig 1B). Only a few CD3+ cells in tumours were double-stained with IL17 antibody (fig 1c).
Elucidation of the nature of the intratumoural inflammatory reaction is relevant not only to understand better the pathobiology of CRCs but also to assess the possible influence of the host immune response on patient outcome. Our study examined the differences in the pattern of inflammatory and immune response markers expressed in the tumour microenvironment of a series of 45 tumours from patients with sporadic CRC. About one-third of the patients had MSI-H colorectal cancer, although no-one displayed HNPCC syndrome and/or the Bethesda criteria.27 MSI-H phenotype tumours, as assessed by immunohistochemistry, showed more pronounced lymphocytic infiltration than MSS phenotype tumours. The MSI-H phenotype was associated with a higher expression level of cytotoxic cell markers, especially perforin. Conversely, the MMR-proficient (MSS) phenotype was associated with higher expression levels of Foxp3, a marker of regulatory T cells, and of inflammatory (IL1β, IL6, IL8, IL17) or suppressive (TGFβ) cytokines, with IL17 expressed at particularly high levels. No difference was observed between MSI-H and MSS tumours regarding CD4+ Th1 and Th2 cell subset infiltration, as assessed by the mRNA levels of the relevant cytokines (IFNγ, TNFα and IL4). Thus, we show for the first time a paradoxical gene expression signature combining markers associated with inhibition of the antitumour immune response (TGFβ, Foxp3) and the protumoural inflammatory response (IL17, IL6) in the microenvironment of sporadic CRCs without microsatellite instability.
Pronounced lymphocytic infiltration is linked with longer survival in human cancers,16 28–31 and immune suppression clearly enhances the chance of cancer appearance in human and animal models.32 However, the lack of tumour immune surveillance has been associated with the context of an inflammatory cytokine milieu (IL6, IL1β, TNFα, IL17).33 34 Thus, the phenotypic and functional characterization of these lymphocytic infiltrates (ie, CD8+ T cells (central and effector memory CD8+ T cells) and CD4+ T cells (CD4+ T helper cells of types 1, 2 and 17), and regulatory/suppressive CD4+ CD25+high T cells (Treg cells)] have been proven to predict prognoses in melanoma, ovarian cancer and non-Hodgkin’s lymphoma.35 36 Together, the data from human studies support the existence of a cancer immunosurveillance system that involves Th1-dependent cytotoxic cells and which is locally suppressed by Treg cells and inflammatory products.
In CRC, the role of tumour-infiltrating inflammatory cells and lymphocytes is still controversial. An increased number of inflammatory cells in tumours may favour tumour progression.21 Increased expression of cytotoxic CD8-positive T cells and increased apoptosis of tumour cells were demonstrated in small series of MSI-H CRCs by using immunohistochemical methods,17 37 38 by assessment of cytotoxic marker mRNA levels (such as perforin and GzB)39 and by using oligonucleotide microarray analysis and/or qRT-PCR assays.40–42 Different findings support the hypothesis that MSI-H CRCs, which are roughly considered to display a good prognosis,43 44 may lead to the production of genetically altered proteins in the tumour microenvironment. These proteins may function as tumour-specific neoantigens able to elicit potentially effective antitumour cytotoxic responses.17 Our results provide additional evidence of the close relationship between pronounced lymphocytic infiltration and the overexpression of cytotoxic markers in MSI-H tumours, indicating a better cell-mediated tumour-specific immune response in patients. Although CRCs in general are known as poor immunogenic tumours,45 those with the MSI-H phenotype should be considered as immunogenic. However, the majority of CRCs are of the MSS phenotype. Together with the low density of the CD3-positive lymphocytic infiltrate and the low perforin expression, this phenotype could reflect the poor immunogenic capacity to generate a specific cytotoxic CD8+ T cell response. Recently, immunological data—for example, the presence of markers for TH1 and cytotoxic polarisation, the memory T cell type, a high density and location of immune cells within the tumour samples—were found to be a better predictor of patient survival than the histopathological methods currently used to stage CRC.46 47 The molecular phenotype of human CRC based on MMR status has not been taken into consideration in these two latter studies. Because the MSI-H phenotype is usually described in only 15–20% of sporadic CRCs, it is unlikely that all tumours (88 out of 104) presenting with a higher density of CD3+ plus CD45+ cells and with longer duration of disease-free survival in related patients, in this series,46 47 might be of the MSI-H phenotype. Thus, MSI-H CRC may still be considered as a single prognostic marker in CRC.
We report for the first time the coexistence of higher expression of markers associated with the antitumour immune response (Foxp3 and TGFβ) and of the two inflammatory cytokines IL6 and IL17, in MMR-proficient CRC. The higher expression of Foxp3 in the current study could be the hallmark of either naturally occurring, thymically produced nTreg cells or extrathymically generated Tr1/Th3 cell infiltrates. The extrathymic T cells are distinct from thymically produced nTreg cells, because they generally do not need contact-dependent mechanisms and may react to soluble cytokines (typically IL10 or TGFβ; for a review, see Fehervari et al.48) Although CD25+ CD4+ T cells could be generated, in vitro, from peripheral naïve CD4+ T cells of Foxp3 reporter mice,49 there is no evidence that these events could occur in physiological conditions and/or in tumour-induced immune responses in vivo. However, these unknowns do not undermine the pluripotential role of TGFβ in the maintenance of Foxp3 expression, regulatory function and homeostasis in peripheral CD4(+)CD25(+) regulatory T cells,50 and well established Foxp3-dependent suppressive abilities of extrathymically generated Tr1/Th3 cells.51 Moreover, the immunosuppressive capability of TGFβ is alternatively supported by its ability to prevent the maturation of dendritic cells (DCs) by maintaining a low expression of costimulatory molecules52 53 and by generating DCs that promote Treg-dependent tolerance.54 Alternatively, tumour cells produce soluble factors such as IL6 that cause a specific DC subset to secrete bioactive TGFβ, which in turn acts as a costimulator of the expansion of Foxp3-expressing Treg cells.55 Thus, in our study, the higher expression of TGFβ, whatever the nature of the TGFβ-secreting cells (eg, Treg cells tumour cells or fibroblasts), could participate to the induction of suppressive mechanisms inducing tumour tolerance in the MSS tumour tissues.
Of potential interest for further functional investigation is analysis of the coexpression of cytokines—for example, IL17A-expressing cells, in the context of IL6 and TGFβ expression in MSS tumour tissues. Although the differentiation of TH-17 cells was described to be determined by exposure to TGFβ and IL6,56 57 we cannot definitively conclude whether the changes in cytokine gene expression in MSS tumours are caused by tumour-infiltrating lymphocytes or innate immune cells, rather than by tumour-infiltrating fibroblasts. Using double staining procedures on immunocytochemistry, we could show that the minority of IL17-immunostained cells were also of the CD3 phenotype. This is consistent with data from the literature indicating that <15% of CD4+ conventional T cells are IL17 (TH-17) when about 60% of the IL17A-producing cells are γδT cells, and 25% are natural killer T-like cells. TH-17 cells coexpress IL17 and IL22.58 In an attempt to discriminate further between the three types of IL17-secreting T cells, we quantified IL22 expression in the same set of MSS and MSI-H tissue samples and autologous controls, and found higher IL22 expression levels in MSS tumours than in MSI-H tumour tissues. Although indirect, this result supports the hypothesis of a higher infiltration of MSS tumours by TH-17 cells, potentially linked to the simultaneous higher expression of TGFβ and IL6 in the microenvironment of MSS tumours. Our results are in agreement with those of different studies showing that the enhanced tumour growth elicited by IL17 was associated both with its proangiogenic effect59 and with the increased expression of IL6 at the tumour site.60 Our data are also consistent with a previous report conducted in a murine tumour model. It showed that IL17 may exert protumour or antitumour effects, depending on the immunogenicity of the tumour and the presence of specific cytolytic T lymphocytes.61 Although further investigations are needed to clarify the cellular sources of TGFβ, IL6 and IL1735 62 we think it is worth considering that the poorly immunogenic MSS tumour might generate regulatory T cells instead of antitumour effector cytotoxic cells, leading to exacerbation, and not to control, of the disease. We would suggest that the coexistence of higher Foxp3, IL6, TGFβ and IL17 expression represents a potential biomarker for the future development of a new prognostic “test set” for sporadic colon cancer.
We would like to thank Professor Philipe Gaulard, Mrs Nadine Martin Garcia, and Mr and Mrs Feriel Bouabbas for their management and technical assistance. We also thank the “Ligue Nationale Contre le Cancer LNCC” and ACD (Association Charles Debray) for their financial support.
web only appendix 57/6/772
Funding: Supported by grants from DRCD Assistance Publique-Hôpitaux de Paris, Ligue Contre le Cancer, ACD.
Competing interests: None.
Ethics approval: The ethical committee approved the procedure.
Patient consent: Patients were routinely informed about biological research on tissues that did not include hereditary genetic characterisation and their tissue materials was used for the current study except if “formal opposition” was mentioned to doctors.